Congenital sideroblastic anemia (CSA) is a dyserythropoietic disorder that leads to transfusion dependency and subsequent iron overload. Nonmyeloablative allogeneic hematopoietic stem cell transplantation (NST) was performed for a patient with CSA, who had contraindications to conventional allografting. Conditioning was fludarabine, low-dose total body irradiation and antithymocyte globulin, followed by peripheral blood stem cell transplant. Cyclosporine and mycophenolate mofetil were used for graft-versus-host disease prophylaxis. Complete donor chimerism was observed day +131. Early after transplant, the patient became transfusion independent, allowing a regular phlebotomy program. On day +190, refractory lactic acidosis followed by fatal cardiovascular collapse developed, without evidence of infection. Data from this case demonstrates that NST may correct the erythropoietic defect of CSA.
stem cell transplantation; congenital sideroblastic anemia; secondary hemochromatosis; iron poisoning; mixed chimerism Congenital sideroblastic anemia (CSA) is a rare genetic dyserythropoietic disorder caused by a mutation in the erythroid d-aminolevulinic acid synthase. 1 The disease is characterized by a hypoproliferative anemia and erythroid hyperplasia of the bone marrow with ring sideroblasts. 2 Ineffective erythropoiesis and red-cell transfusions lead to secondary hemochromatosis, and survival is seldom beyond the second decade. 3 Conventional allogeneic hematopoietic stem cell transplantation (alloHSCT) has been successful for CSA in two cases. 2, 4 Nonmyeloablative allogeneic hematopoietic stem cell transplantation (NST) for CSA has not been reported.
Case report
The patient was a 22-year-old male first diagnosed with CSA at 8 months of age with a qualitative defect of erythroid d-aminolevulinic acid synthase. Secondary hemochromatosis was present with progressively worsening cardiomyopathy and frequent episodes of supraventricular tachyarrhythmia. Pyridoxine therapy was ineffective and desferrioxamine had been used for 10 years. A systolic ejection murmur and hepatomegaly were present on physical examination. Laboratory values are shown in Table 1 . Bone marrow (BM) morphology showed erythroid hyperplasia and ringed sideroblasts with normal megakaryocytopoieisis and myelopoieisis. BM cytogenetics was normal. Liver biopsy revealed mild bridging fibrosis with an iron content of 50 mg/g of tissue. Echocardiogram showed a mild systolic dysfunction, mild diastolic dysfunction and severe pulmonary hypertension. Pulmonary function tests demonstrated a restrictive pattern with reduced carbon monoxide diffusion capacity (DLCO-30%).
Owing to a projected high risk of treatment-related mortality with a conventional allograft the patient was offered an NST. A modified Seattle regimen 6 was used including fludarabine 25 mg/m 2 /day intravenously on days À6 to À2, rabbit antithymocyte globulin 2.5 mg/kg/day intravenously on days À6 to À4, and one fraction of total body irradiation (TBI), 200 cGy, on day 0. On day 0, G-CSF mobilized peripheral blood stem cells from his human leukocyte antigen (HLA)-identical brother were infused. These contained 4.41 Â 10 6 CD34 + cells/kg and 4 Â 10 8 CD3 + cells/kg. Planned graft-versus-host disease (GVHD) prophylaxis was cyclosporine until day +180 and mycophenolate mofetil (MMF) until day +40.
Myelosuppression was relatively mild and slow-onset. The absolute neutrophil count was o0.5 Â 10 /weekly) was initiated together with subcutaneous desferrioxamine 1500 mg/day and Erythopoietin 10 000 IU three times/ week, in an attempt to deplete iron stores (Table 1) .
Transplant-related toxicities (TRT) included cholestatic liver disease and renal insufficiency primarily caused by cyclosporine. On day +110, GVHD of stomach and duodenum was diagnosed by biopsy and responded to treatment with prednisone and MMF. The subsequent course was marked by recurrent admissions, mostly for management of GVHD. On day +190, the patient presented with lethargy and drowsiness secondary to narcotic use for hip pain. He suddenly developed lactic acidosis and refractory tissue hypoxia, followed by laboratory evidence of shock liver and subsequently cardiovascular collapse that were unresponsive to medical therapy. All blood cultures remained negative and there was no definitive laboratory evidence of infection. Autopsy samples showed full donor chimerism, evidence of hepatic centrilobular necrosis, and diffuse iron deposition in the heart, liver, spleen and adrenal gland. There was no evidence of infection. 
Discussion
CSA is characterized by defective heme biosynthesis causing impaired utilization of iron by erythroblasts. 2 Owing to ineffective erythropoiesis and the need for redcell transfusions, secondary hemosiderosis develops despite chelation therapy. 3 AlloHSCT has been reported in two cases of CSA, 2,4 both without end-organ dysfunction caused by iron overload. The engraftment and chimerism data of our case show that NST can correct the dyserythropoiesis in CSA, and may be a potential curative alternative to conventional allografts.
NST have recently been investigated for malignant and genetic disorders 5 with the goal to establish full-donor or mixed donor/host chimerism. Mixed chimerism with only 20-30% of donor cells may suffice to correct phenotypic manifestations of genetic hematological diseases. 6 The use of lower intensity conditioning regimens should reduce TRT and therefore the risks of transplant mortality. 7 Concerns about pre-existing alloimmunization, increasing the potential for graft rejection, prompted us to add ATG to the previously established fludarabine-TBI regimen. 8 Initial T-cell chimerism levels were relatively low and in a range associated with increased rejection risk. 8 After remaining stable for several months, donor chimerism increased spontaneously in association with development of GVHD after tapering of MMF. The increase in chimerism was likely mediated by GVHD, suggesting that stable highlevel donor engraftment would have persisted if the patient had survived.
Despite multiple comorbid conditions, the transplant was initially well tolerated without severe toxicities, as mucositis or prolonged pancytopenia. Later problems included cyclosporine-related hepatotoxicity and nephrotoxicity, infections and GVHD; many of which were likely related to the poor underlying condition of the patient. Thus, it would be preferable to perform such transplants before serious cardiac and liver disease develops. 4 The fate of iron stores in secondary hemochromatosis after HSCT has been elucidated. 9 Establishing normal erythropoiesis by itself, achieves only very limited iron excretion. Routine phlebotomy programs are required to efficiently mobilize iron from overloaded tissues 9 , and may reverse cirrhosis 10 and cardiac dysfunction secondary to hemosiderosis. 11 With weekly phlebotomies, iron chelation therapy and erythropoietin, iron overload decreased in this case suggesting that iron overload and end-organ dysfunction might eventually have improved significantly. 11 These results demonstrate that NST may be a potentially curative therapy for CSA. Iron overload could be corrected, after transplant, by venesection. The mild early regimen-related toxicities 8 suggest that this approach would be preferable to conventional allografting.
